Glucocorticoid Therapy for Early Intervention in Quick Progression of Hospitalized Patients with COVID-19

doi:10.19803/j.1672-8629.2021.10.03

Abstract

Abstract: Objective To explore the clinical application of sequential therapy with dexamethasone 10mg/5mg in the treatment of COVID-19. Methods Cases of COVID-19 who were hospitalized in Beijing Ditan Hospital between January 20, 2020 and March 20, 2021 were retrospectively investigated. By propensity score matching, 32 patients in the glucocorticoid-treated group and another 32 patients in the control group were selected. Results Compared with the control group, the duration of oxygen inhalation, time taken by chest improvement shown by CT, clinical complete remission and the proportion of patients treated in ICUs in the glucocorticoid group were significantly shortened or reduced. On the fourth, seventh and fourteenth day of the course, levels of C-reactive protein and NE/LY recovered quickly（P<0.01）. AI-assisted CT showed that there was significant difference in the volume of inflammation lesions of the total lung and average density of lesions of the total lung between the two groups on the fourth day of the course（P<0.05）. There was significant difference in the percentage of volumes of inflammation lesions of the total lung on the fourth and seventh day of the course（P<0.05）. There was no statistically significant difference in the time taken by clearance of SARS-CoV-2 RNA and lengths of hospital stay between the two groups（P>0.05）. Conclusion Dexamethasone 10mg/5mg sequential therapy may be an effective treatment for progression of hospitalized patients with COVID-19, and can be tried in the process of diagnosis and treatment.

Key words: SARS-CoV-2, COVID-19, glucocorticoid, dexamethasone, clinical application, propensity score

CLC Number:

R978.7

LI Xingang, GUAN Chunshuang, LU Xingmeng, MU Xuechun, WANG Aibin, ZHANG Tingyu, GE Ziruo, XU Yanli, CHEN Zhihai, SONG Rui. Glucocorticoid Therapy for Early Intervention in Quick Progression of Hospitalized Patients with COVID-19[J]. Chinese Journal of Pharmacovigilance, 2021, 18(10): 910-914.

References

[1] Linas C, Perra L, Aiello M, et al.A critical evaluation of glucocorticoids in the management of severe COVID-19[J]. Cytokine & Growth Factor Reviews, 2020, 54: 28-23.
[2] Van Paassen J, Vos JS, Hoekstra EM, et al.Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes[J]. Crit Care, 2020,24(1): 696.
[3] Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and network meta-analysis [J/OL]. BMJ. (2020-07-30)[2021-04-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390912/.
[4] Zhou W, Liu Y, Tian D, et al.Potential benefits of precise corticos-teroids therapy for severe 2019-nCoV pneumonia[J]. Signal Transduct Target Ther, 2020, 5(1): 18.
[5] World Health Organization. Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: Interim Guidance[EB/OL].(2020-01-12) [2020-03-19]. https://apps.who.int/iris/handle/10665/330893.
[6] Russell CD, Millar JE, Baillie JK.Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury[J]. Lancet, 2020, 395(10223): 473-475.
[7] Horby P, Lim WS, Emberson JR, et al.Dexamethasone in hospitalized patients with covid-19: preliminary report[J]. N Engl J Med, 2021, 384(8): 693-704.
[8] Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: a meta-analysis [EB/OL].JAMA. (2020-09-02)[2020-12-02]. https://jamanetwork.com/journals/jama/fullarticle/2770279.
[9] Beigel JH, Tomashek KM, Dodd LE, et al.Remdesivir for the treatment of Covid-19 - Final Report[J]. N Engl J Med, 2020, 383(19): 1813-1826.
[10] Maskin LP, Olarte GL, Palizas FJ, et al.High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial[J]. Trials, 2020,21(1): 743.
[11] Maláska J, Stašek J, Duška F, et al.Effect of dexamethasone in patients with ARDS and COVID-19 - prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): a structured summary of a study protocol for a randomised controlled trial[J]. Trials, 2021, 22(1): 172.
[12] Hoffmann M, Kleine-Weber H, Schroeder S, et al.SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J]. Cell, 2020, 181(2): 271-280.
[13] Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosup-pression[J]. Lancet, 2020, 395(10229): 1033-1034.
[14] Xu Z, Shi L, Wang Y, et al.Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med, 2020, 8(4): 420-422.
[15] Xiao Y, Guo YM, Yiu Y. The role of medical imaging in the diagnosis and treatment of COVID-19[J/OL]. Chinese Journal of Radiology (中国放射医学杂志).(2020-02-12) [2020-04-20]. http://rs.yiigle.com/yufabiao/1180540.htm.
[16] Asselah T, Durantel D, Pasmant E, et al.COVID-19: discovery, diagnostics and drug development[J]. J Hepatol, 2021, 74(1): 168-184.
[17] Griffith JF, Antonio GE, Kumta SM, et al.Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids[J]. Radiology, 2005, 235(1): 168-175.
[18] Sung JJ, Wu A, Joynt GM, et al.Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak[J]. Thorax, 2004, 59(5): 414-420.
[19] Auyeung TW, Lee JS, Lai WK, et al.The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study[J]. J Infect, 2005, 51(2): 98-102.
[20] Li XG, Xu YL, Wang L, et al.Clincal research of glucocorticoid treatment in severe cases of COVID-19[J]. Journal of Capital Medical University(首都医科大学学报), 2020, 41(3): 345-349.
[21] Sanders JM, Monogue ML, Jodlowski TZ, et al.Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review[J]. JAMA, 2020, 323(18): 1824-1836.